Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012-2013).
暂无分享,去创建一个
C. Rizzo | S. Iannazzo | G. Fedele | M. C. Rota | M. Carollo | A. Giammanco | C. Ausiello | R. Palazzo | Sero-Epidemiology Working Group | M. Rota
[1] G. Fedele,et al. T-cell immune responses to Bordetella pertussis infection and vaccination. , 2015, Pathogens and disease.
[2] Qiushui He,et al. Seroprevalence studies of pertussis: what have we learned from different immunized populations. , 2015, Pathogens and disease.
[3] H. Goossens,et al. Prevalence, diagnosis, and disease course of pertussis in adults with acute cough: a prospective, observational study in primary care , 2015, The British journal of general practice : the journal of the Royal College of General Practitioners.
[4] E Rizzuto,et al. Epidemiology of pertussis in Italy: disease trends over the last century. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[5] S. Plotkin. The pertussis problem. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Jeff F. Miller,et al. Bordetella pertussis pathogenesis: current and future challenges , 2014, Nature Reviews Microbiology.
[7] A. Linneberg,et al. Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark , 2013, Epidemiology and Infection.
[8] P. Melin,et al. Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012 , 2013, Epidemiology and Infection.
[9] A. Tozzi,et al. Attitude of Italian physicians toward pertussis diagnosis , 2013, Human vaccines & immunotherapeutics.
[10] E. Chiappini,et al. Pertussis re-emergence in the post-vaccination era , 2013, BMC Infectious Diseases.
[11] K. Macartney,et al. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. , 2013, Vaccine.
[12] J. Mertsola,et al. High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[13] P. van Damme,et al. Rationale for pertussis booster vaccination throughout life in Europe. , 2011, The Lancet. Infectious diseases.
[14] F. Mooi,et al. Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of Bordetella pertussis , 2010, PloS one.
[15] G. Berbers,et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories , 2010, European Journal of Clinical Microbiology & Infectious Diseases.
[16] H. Hallander,et al. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[17] H. Hallander,et al. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[18] M. Corbel,et al. Characterization of Reference Materials for Human Antiserum to Pertussis Antigens by an International Collaborative Study , 2008, Clinical and Vaccine Immunology.
[19] R. Pebody,et al. European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations. , 2008, Vaccine.
[20] C. Siegrist,et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. , 2008, The Journal of pediatrics.
[21] V. Boddi,et al. Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy , 2008, Epidemiology and Infection.
[22] F. Noya,et al. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. , 2007, Vaccine.
[23] M. Hudgens,et al. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants , 2007, Emerging themes in epidemiology.
[24] J. Mertsola,et al. Immunity to pertussis 5 years after booster immunization during adolescence. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] J. Cherry. Immunity to pertussis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] M. Massari,et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. , 2005, Vaccine.
[27] Seema Mattoo,et al. Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies , 2005, Clinical Microbiology Reviews.
[28] J. Schellekens,et al. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis , 2005, Epidemiology and Infection.
[29] J. Schellekens,et al. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. , 2003, Vaccine.
[30] L. Ravà,et al. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. , 2003, Pediatrics.
[31] S. Salmaso,et al. Pediatric sentinel surveillance of vaccine-preventable diseases in Italy , 2002, The Pediatric infectious disease journal.
[32] E. L. Miller,et al. The sero-epidemiology of diphtheria in Western Europe , 2000, Epidemiology and Infection.
[33] E. Kerem,et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. , 1999, Chest.
[34] M. Steinhoff,et al. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. , 1995, Pediatrics.
[35] W. Blackwelder,et al. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. , 1995, Journal of immunological methods.
[36] S. Salmaso,et al. Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. , 1992, The Pediatric infectious disease journal.
[37] S. Long,et al. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. , 1990, The Journal of infectious diseases.
[38] M. Decker,et al. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. , 2018, Vaccine.
[39] F. Noya,et al. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. , 2012, Vaccine.
[40] Pertussis vaccines--WHO position paper. , 2005, Releve epidemiologique hebdomadaire.
[41] Regina Elena. Childhood vaccination coverage in Italy: results of a seven-region survey. The Italian Vaccine Coverage Survey Working Group. , 1994, Bulletin of the World Health Organization.
[42] S. Salmaso,et al. Childhood Vaccination Coverage in Italy: Results of a Seven-Region Survey , 1994 .